Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Recent Advancement for the Treatment of Hepatocellular Carcinoma
share announcement

Recent Advancement for the Treatment of Hepatocellular Carcinoma

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 7437

Special Issue Editor

Dr. Kazuhiro Nouso

E-Mail Website
Guest Editor
Department of Gastroenterology and Liver Disease Center, Okayama City Hospital, Okayama City, Japan
Interests: hepatocellular carcinoma; local ablation therapy; MTAs; cancer biology

Special Issue Information

Dear Colleagues,

Hepatocellular carcinoma (HCC) is a major cause of death worldwide. Due to the eradication of hepatitis C virus by direct-acting antivirals and the suppression of hepatitis B virus replication by nucleoside analogs, the number of viral-related HCC cases is gradually decreasing. On the contrary, nonviral-related HCC in individuals with alcoholic liver disease and/or metabolic liver disease is increasing and is now an important public health concern.

Recently, many new therapeutic modalities for the treatment of HCC, such as the next-generation microwave coagulation system, have been developed. In addition, multiple chemotherapy drugs have become available in recent years, and thus, the landscape of liver cancer treatment has changed dramatically. These developments have provided us with effective tools to combat HCC, but simultaneously, the way in which these modalities are used to treat HCC has become complex. In this special issue, experts on each topic will review recent advancements in their field and give us suggestions to manage the leading developments in the effective treatment of HCC.

Dr. Kazuhiro Nouso
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hepatocellular carcinoma
  • treatment
  • resection
  • local ablation therapy
  • transcatheter arterial chemoembolization
  • hepatic arterial infusion chemotherapy
  • molecular target agents
  • immunotherapy
  • radiation therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Editorial

Jump to: Review

2 pages, 167 KiB  
Editorial
Recent Advancements for the Treatment of Hepatocellular Carcinoma
by Kazuhiro Nouso
Cancers 2023, 15(18), 4444; https://doi.org/10.3390/cancers15184444 - 6 Sep 2023
Viewed by 1465
Abstract
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide and is currently one of the most common cancers [...] Full article
(This article belongs to the Special Issue Recent Advancement for the Treatment of Hepatocellular Carcinoma)

Review

Jump to: Editorial

14 pages, 1613 KiB  
Review
Tips for Preparing and Practicing Thermal Ablation Therapy of Hepatocellular Carcinoma
by Yasunori Minami, Tomoko Aoki, Satoru Hagiwara and Masatoshi Kudo
Cancers 2023, 15(19), 4763; https://doi.org/10.3390/cancers15194763 - 28 Sep 2023
Cited by 17 | Viewed by 3506
Abstract
Thermal ablation therapy, including radiofrequency ablation (RFA) and microwave ablation (MWA), is considered the optimal locoregional treatment for unresectable early-stage hepatocellular carcinomas (HCCs). Percutaneous image-guided ablation is a minimally invasive treatment that is being increasingly performed because it achieves good clinical outcomes with [...] Read more.
Thermal ablation therapy, including radiofrequency ablation (RFA) and microwave ablation (MWA), is considered the optimal locoregional treatment for unresectable early-stage hepatocellular carcinomas (HCCs). Percutaneous image-guided ablation is a minimally invasive treatment that is being increasingly performed because it achieves good clinical outcomes with a lower risk of complications. However, the physics and principles of RFA and MWA markedly differ. Although percutaneous thermal ablation under image guidance may be challenging in HCC cases with limited access or a risk of thermal injury, a number of ablative techniques, each of which may be advantageous and disadvantageous for individual cases, are available. Furthermore, even when a HCC is eligible for ablation based on tumor selection and technical factors, additional patient factors may have an impact on whether it is the appropriate treatment choice. Therefore, a basic understanding of the advantages and limitations of each ablation device and imaging guidance technique, respectively, is important. We herein provide an overview of the basic principles of tissue heating in thermal ablation, clinical and laboratory parameters for ablation therapy, preprocedural management, imaging assessments of responses, and early adverse events. We also discuss associated challenges and how they may be overcome using optimized imaging techniques. Full article
(This article belongs to the Special Issue Recent Advancement for the Treatment of Hepatocellular Carcinoma)
►▼ Show Figures

Figure 1

11 pages, 524 KiB  
Review
Image-Guided Ablation Therapies for Extrahepatic Metastases from Hepatocellular Carcinoma: A Review
by Noriyuki Umakoshi, Yusuke Matsui, Koji Tomita, Mayu Uka, Takahiro Kawabata, Toshihiro Iguchi and Takao Hiraki
Cancers 2023, 15(14), 3665; https://doi.org/10.3390/cancers15143665 - 18 Jul 2023
Cited by 2 | Viewed by 1762
Abstract
The most common sites of extrahepatic metastases from hepatocellular carcinoma (HCC) are the lungs, intra-abdominal lymph nodes, bones, and adrenal glands, in that order. Although systemic therapies are a common treatment for patients with extrahepatic metastases, local ablative therapies for the extrahepatic metastatic [...] Read more.
The most common sites of extrahepatic metastases from hepatocellular carcinoma (HCC) are the lungs, intra-abdominal lymph nodes, bones, and adrenal glands, in that order. Although systemic therapies are a common treatment for patients with extrahepatic metastases, local ablative therapies for the extrahepatic metastatic lesions can be performed in selected patients. In this article, the literature on image-guided thermal ablation for metastasis to each organ was reviewed to summarize the current evidence. Radiofrequency ablation was the most commonly evaluated technique, and microwave ablation, cryoablation, and percutaneous ethanol injection were also utilized. The local control rate of thermal ablation therapy was relatively favorable, at approximately 70–90% in various organs. The survival outcomes varied among the studies, and several studies reported that the absence of viable intrahepatic lesions was associated with improved survival rates. Since only retrospective data from relatively small studies has been available thus far, more robust studies with prospective designs and larger cohorts are desired to prove the usefulness of thermal ablation for extrahepatic metastases from HCC. Full article
(This article belongs to the Special Issue Recent Advancement for the Treatment of Hepatocellular Carcinoma)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop